Share on StockTwits

Analysts at Piper Jaffray hoisted their price target on shares of Amedisys (NASDAQ:AMED) from $12.00 to $18.00 in a research report issued to clients and investors on Thursday. The firm currently has a “neutral” rating on the stock. Piper Jaffray’s target price points to a potential downside of 7.69% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group raised their price target on shares of Amedisys from $12.00 to $16.50 in a research note on Thursday. They now have a “hold” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Amedisys from $7.00 to $10.00 in a research note on Friday, July 18th. They now have an “underperform” rating on the stock. Finally, analysts at Deutsche Bank upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Monday, June 30th. They now have a $14.00 price target on the stock, up previously from $8.00. Two investment analysts have rated the stock with a sell rating and nine have issued a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $17.06.

Shares of Amedisys (NASDAQ:AMED) traded down 3.42% on Thursday, hitting $19.49. The stock had a trading volume of 472,502 shares. Amedisys has a one year low of $12.60 and a one year high of $20.93. The stock has a 50-day moving average of $15.61 and a 200-day moving average of $15.05. The company’s market cap is $647.7 million.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 30th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.04 by $0.21. The company had revenue of $305.00 million for the quarter, compared to the consensus estimate of $298.90 million. During the same quarter in the prior year, the company posted $0.17 earnings per share. The company’s quarterly revenue was down 3.5% on a year-over-year basis. Analysts expect that Amedisys will post $0.16 EPS for the current fiscal year.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.